Evommune (EVMN) Current Deferred Revenue (2024)
Evommune (EVMN) posted quarterly Current Deferred Revenue of $3.0 million for Q4 2024.
Powered by 
Analysis
Evommune (EVMN) Current Deferred Revenue (2024) Analysis & Trends
Evommune (EVMN) has reported Current Deferred Revenue for 1 consecutive years, with $3.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Current Deferred Revenue changed N/A year-over-year to $3.0 million; the TTM figure through Dec 2024 stood at $3.0 million (changed N/A YoY), while the FY2024 annual figure was $3.0 million, changed N/A from the prior year.
- Current Deferred Revenue steadied at $3.0 million in Q4 2024 per EVMN's latest filing.
- Across five years, Current Deferred Revenue topped out at $3.0 million in Q4 2024 and bottomed at $3.0 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Evommune | 448.44 Mn | 247.65 Mn | - |